These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27998182)

  • 1. Investigation of transrenal KRAS mutation in late stage NSCLC patients correlates to disease progression.
    Wang X; Meng Q; Wang C; Li F; Zhu Z; Liu S; Shi Y; Huang J; Chen S; Li C
    Biomarkers; 2017 Nov; 22(7):654-660. PubMed ID: 27998182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients.
    Li F; Huang J; Ji D; Meng Q; Wang C; Chen S; Wang X; Zhu Z; Jiang C; Shi Y; Liu S; Li C
    Clin Transl Oncol; 2017 Oct; 19(10):1283-1291. PubMed ID: 28497422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary cell-free DNA as a prognostic marker for KRAS-positive advanced-stage NSCLC.
    Xie F; Li P; Gong J; Tan H; Ma J
    Clin Transl Oncol; 2018 May; 20(5):591-598. PubMed ID: 28956302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.
    Camps C; Jantus-Lewintre E; Cabrera A; Blasco A; Sanmartín E; Gallach S; Caballero C; del Pozo N; Rosell R; Guijarro R; Sirera R
    Lung Cancer; 2011 Jun; 72(3):365-9. PubMed ID: 21074889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
    Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential use of transrenal DNA for non-invasive monitoring and prognosis of colorectal cancer.
    Chen W; Liao Y; Yang C; Fang Z; Liu B; Zheng X; Zhou C
    Biomarkers; 2019 Sep; 24(6):524-529. PubMed ID: 31220949
    [No Abstract]   [Full Text] [Related]  

  • 8. Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.
    Guibert N; Pradines A; Farella M; Casanova A; Gouin S; Keller L; Favre G; Mazieres J
    Lung Cancer; 2016 Oct; 100():1-4. PubMed ID: 27597273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of
    Michaelidou K; Koutoulaki C; Mavridis K; Vorrias E; Papadaki MA; Koutsopoulos AV; Mavroudis D; Agelaki S
    Cells; 2020 Nov; 9(11):. PubMed ID: 33233668
    [No Abstract]   [Full Text] [Related]  

  • 10. KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.
    Pan W; Yang Y; Zhu H; Zhang Y; Zhou R; Sun X
    Oncotarget; 2016 Feb; 7(7):8373-88. PubMed ID: 26840022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
    Nygaard AD; Garm Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Lung Cancer; 2013 Mar; 79(3):312-7. PubMed ID: 23238036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of transrenal DNA with non-small-cell lung cancer in noninvasive disease monitoring.
    Zhu Z; Li F; Wang X; Li C; Meng Q; Wang C; Huang J; Chen S; Wu X
    Biomark Med; 2021 Nov; 15(16):1553-1562. PubMed ID: 34651512
    [No Abstract]   [Full Text] [Related]  

  • 15. Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma.
    Wagner PL; Stiedl AC; Wilbertz T; Petersen K; Scheble V; Menon R; Reischl M; Mikut R; Rubin MA; Fend F; Moch H; Soltermann A; Weder W; Altorki NK; Perner S
    Lung Cancer; 2011 Oct; 74(1):118-23. PubMed ID: 21477882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
    Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF
    J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA as prognostic markers for late stage NSCLC with bone metastasis.
    Jia J; Huang B; Zhuang Z; Chen S
    Int J Biol Markers; 2018 May; 33(2):222-230. PubMed ID: 29712496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
    Macerelli M; Caramella C; Faivre L; Besse B; Planchard D; Polo V; Ngo Camus M; Celebic A; Koubi-Pick V; Lacroix L; Pignon JP; Soria JC
    Lung Cancer; 2014 Mar; 83(3):383-8. PubMed ID: 24439569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer.
    Zulato E; Attili I; Pavan A; Nardo G; Del Bianco P; Boscolo Bragadin A; Verza M; Pasqualini L; Pasello G; Fassan M; Calabrese F; Guarneri V; Amadori A; Conte P; Indraccolo S; Bonanno L
    Br J Cancer; 2020 Jul; 123(1):81-91. PubMed ID: 32376889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variations in transrenal DNA and comparison with plasma DNA as a diagnostic marker for colorectal cancer.
    Tian F; Liao Y; Zhang Y
    Int J Biol Markers; 2017 Oct; 32(4):e434-e440. PubMed ID: 28708207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.